Teva Stands By Orange Book Listings As FTC Takes Further Action
Firm Responds To Reports Of FTC Investigation Over Inhaler Patents, After Refusal To Delist
Following reports of the FTC escalating its investigations into Teva over inhaler patents listed in the FDA’s Orange Book, the firm is standing by its intellectual property.
